Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia

Status unconfirmed · Phase 4

Conditions studied: Alopecia

In brief

The purpose of this study is to ascertain the safety and efficacy of Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal Cicatricial Alopecia.

Key facts

Study ID

NCT01111981

Run by

Callender Center for Clinical Research

People needed

30

Starts

2009-10-01

Expected to finish

2010-10-01

Last updated by the study team

2010-04-28

Who can join

Age: 18 and older, up to 80. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients with CCCA, treated or untreated
• Score 0 - 1 on Scale/Questionnaire
• 18 years of age or older
• Women of African descent

You may not qualify if…

• Score > 1 on Scale/Questionnaire
• Alopecias other than CCCA, including alopecia arreata, lichen planopilaris, trichotillomania, and traction alopecia
• History of hair transplantation
• Children less than 18 years of age
• Males
• Women of non-African descent
• Pregnancy or breastfeeding. Women of childbearing age must use reliable forms of contraception (e.g., abstinence, oral contraceptives, or spermicide and condoms)
• Anti-dandruff shampoo within 30 days
• Anti-inflammatory medications such as antibiotics (doxycycline, minocycline, rifampin, etc.), steroids (oral prednisone, topical corticosteroids,etc.), NSAIDs (ibuprofen, aspirin, etc.)

Where it is running

• Callender Center for Clinical Research — Mitchellville, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.